Emmett V. Schmidt
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)Massachusetts General Hospital(US)National Human Genome Research Institute(US)Cancer Research Center(US)Center for Cancer Research(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cancer-related Molecular Pathways, CAR-T cell therapy research, Cancer Research and Treatments, Epigenetics and DNA Methylation
Most-Cited Works
- → Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice(1994)974 cited
- → Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer(2020)516 cited
- → IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development(2001)479 cited
- → Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial(2019)479 cited
- → The role of c-myc in cellular growth control(1999)381 cited
- → Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)(2018)379 cited